Bluejay Diagnostics reaches 624 patient enrollment in Symphony clinical trial

Bluejay Diagnostics (BJDX) announced the enrollment of 624 patients in its ongoing SYMON-II Trial, a pivotal clinical study evaluating the company’s Symphony platform for interleukin-6 testing in critical care settings to determine patient acuity for sepsis triage and monitoring. The SYMON-II study has a target enrollment of 750 patients, and the company expects to complete enrollment within the next 2 to 3 months, subject to site activity and patient flow. The SYMON-II trial is designed to support the clinical validation of Bluejay’s Symphony IL-6 test, which aims to provide rapid, near-patient results to aid clinicians in assessing patient severity and guiding timely decision-making in acute care environments. With enrollment nearing completion, Bluejay anticipates progressing toward the next phases of clinical validation and regulatory submission activities. The Symphony IL-6 Test to determine patient acuity for sepsis triage and monitoring is currently Bluejay’s lead product candidate.